It has been almost two years since I began the trial with Acalabrutinib, my fourth round of treatment. My counts are all within normal range, and my CD19 has decreased exponentially since the peak lymphocyte count, some two months after I began the study. CD4/CD8 ratio has not improved one whit, nor have immunoglobulin numbers, so I continue at increased risk of infection. Furthermore, I am about to have a basal cell carcinoma surgically excised.
I attach a very good exponential fit to the CD19 data, (using desmos.com to find the fit and plot the results).
All in all, though not cured, I am pleased with my disease management.